ANDA 219701, held by Anthea Pharma. Sodium Bicarbonate.
As of Nov 16, 2026, ANDA 219701 (Sodium Bicarbonate), held by Anthea Pharma, was first approved by FDA on Jun 26, 2025, with 0 approved supplements and 0 published complete response letters.
CONTRAINDICATIONS Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction, and in patients receiving diuretics known to produce a hypochloremic alkalosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Bicarbonate50MEQ/50ML (1MEQ/ML) · solution;intravenous | Sodium Bicarbonate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters